Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company known for its mRNA technology, which has been at the forefront of developing vaccines, including the COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Mar 18, 2026 17:01

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna shares see a dip: what is pressuring the stock

Moderna (MRNA) shares have dipped 3.77% to $51.90, trading below its SMA-20, despite reporting better-than-expected earnings and the FDA initiating a review of its mRNA flu vaccine. This decline is attributed to institutional selling pressure, including Militant Capital Partners LP reducing its stake, and mixed technical indicators creating short-term uncertainty for the stock. Experts offer diverging opinions, with some forecasting continued bullish trends while others warn of significant downside risks.

https://tradersunion.com/news/financial-news/show/1725988-moderna-slides-3-77percent-today-to/

Glaucoma trial tests cannabinoid pill designed to protect vision

Artelo Biosciences (NASDAQ: ARTL) is expanding into the $16.3 billion glaucoma market with a fully funded investigator-sponsored trial for its cannabinoid pill, ART27.13, aimed at protecting vision. The trial will evaluate ART27.13's efficacy in modulating intraocular pressure (IOP) and its neuroprotective properties without central nervous system side effects. This move diversifies Artelo's pipeline without shareholder dilution, capitalizing on a European patent protecting the ART27.13 formulation through 2041, with first patient enrollment expected in Q2 2026.

https://www.stocktitan.net/news/ARTL/vanderbilt-report-artelo-biosciences-expands-into-16-3-billion-06cu7r5zw29a.html

Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks

This article reviews the Q4 earnings performance of several therapeutics companies, highlighting Vertex Pharmaceuticals, Novavax, United Therapeutics, Biogen, and Moderna. It discusses their revenue growth, performance against analyst expectations, and current stock trading prices, noting strong tailwinds for the industry from advancements in precision medicine but also headwinds from drug pricing scrutiny and regulatory unknowns.

https://stockstory.org/us/stocks/nasdaq/vrtx/news/earnings/q4-earnings-outperformers-vertex-pharmaceuticals-nasdaqvrtx-and-the-rest-of-the-therapeutics-stocks

Captrust Financial Advisors Has $137.07 Million Stock Holdings in Amgen Inc. $AMGN

Captrust Financial Advisors has significantly increased its stake in Amgen Inc., boosting its holdings by 5.9% to 485,703 shares valued at $137.07 million. This move is part of a broader trend of institutional investors accumulating substantial positions in the biotechnology company, with major players like Vanguard owning 53.7 million shares. Despite Amgen beating recent quarterly earnings estimates and raising its full-year guidance, analysts maintain a "Hold" rating with an average price target of $354, influenced by concerns such as potential drug-discount initiatives and long-term earnings debate around exclusivity.

https://www.marketbeat.com/instant-alerts/filing-captrust-financial-advisors-has-13707-million-stock-holdings-in-amgen-inc-amgn-2026-03-18/

Pfizer Inc Stock (PFE) Moved Up by 3.89% on Mar 17: What Investors Need To Know

Pfizer Inc. (PFE) saw its stock price increase by 3.89% on March 17, driven by positive Phase 2 results for its atirmociclib (breast cancer) and tilrekimig (atopic dermatitis) drugs, alongside improved analyst sentiment with rating upgrades and price target increases. The company also benefited from increased institutional investment and ongoing investor interest in its obesity drug market strategy. Despite these gains, analysts note a looming patent cliff and concerns regarding the obesity drug pipeline and regulatory friction, posing potential risks for future earnings stability.

https://www.tradingkey.com/news/Market-Movers/261691228-market-movers-pfe-20260317

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 5.2% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.6% Today

Williams-Sonoma Inc. (DE) ($WSM) Stock Forecast: Up 1.7% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.5% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.4% Today

Chipotle Mexican Grill Inc. ($CMG) Stock Forecast: Down 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.1% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 5.3% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 5.4% Today

Moderna Inc. Price History

10.02.2026 - MRNA Stock was up 5.8%

• Moderna's stock surged by 6.13% to an intraday high, showcasing robust investor confidence and market demand for the company's products.
• The company's narrower-than-expected Q4 loss and sales beating estimates indicate a positive financial performance, contributing to the bullish movement.
• Strong short-term gains, including an 89.01% year-to-date increase, coupled with high institutional holdings at 80.65%, further bolster investor sentiment in Moderna.
• Eric Green's retirement at West Pharmaceutical, a key player in vaccine distribution, may have indirectly contributed to positive market sentiment towards Moderna, emphasizing the critical role of vaccine-related companies in the current economic landscape.

04.02.2026 - MRNA Stock was up 7.6%

• Following the announcement of a $950 million settlement to resolve patent infringement claims with Arbutus Biopharma Corp and Genevant Sciences GmbH, Moderna's stock saw a notable bullish trend.
• This settlement eliminated a significant financial risk for Moderna, increasing investor confidence in the company's future.
• Despite the substantial settlement, investors interpreted this news positively for Moderna, resulting in the bullish market movement.
• The information about the settlement overshadowed insider sales at Axsome Therapeutics and routine equity compensation activities at Molson Coors Beverage Co, underscoring the impact of legal resolutions on market sentiment.

04.02.2026 - MRNA Stock was up 13.4%

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

05.02.2026 - MRNA Stock was down 5.5%

• Moderna experienced a bearish movement possibly due to the settlement it reached with Roivant Sciences and Arbutus Biopharma, which involved significant payouts, impacting its financials negatively.
• The positive news of being a top leader among stocks on Wednesday might have been overshadowed by the impact of the settlements on Moderna's finances.
• The increase in headcount by some Massachusetts biotech companies, including Moderna, in 2025, could indicate potential operational expansions that might have been affected by the recent legal settlements.

05.02.2026 - MRNA Stock was up 7.7%

• Moderna's recent positive developments include a substantial $2.25 billion settlement with Roivant Sciences, resolving patent disputes on lipid nanoparticle technology in COVID-19 vaccines. This settlement not only removes a legal overhang but also shows the company's ability to protect its intellectual property rights effectively.
• Another significant development is Moderna's $950 million settlement with Arbutus Biopharma, providing clarity and resolution on a patent infringement lawsuit related to its Covid-19 vaccine, Spikevax.
• The company's decision to add workers in 2025 amidst industry-wide layoffs suggests strategic growth plans and commitment to expanding its workforce to support research and development efforts, potentially boosting investor confidence in the stock.
• These settlements, coupled with workforce expansion and positive industry developments, may have contributed to investor optimism in Moderna, driving its strong bullish movement in the market.

17.02.2026 - MRNA Stock was up 5.5%

• Today's positive movement in Moderna's stock price is linked to a recent federal court decision blocking proposed changes to the U.S. vaccine policy, a move by Health Secretary Robert F. Kennedy Jr. This ruling has provided stability for Moderna amidst concerns of policy changes impacting biotech revenues.
• Noteworthy insider selling by key individuals such as Moderna President Stephen Hoge, alongside decreased stake holdings by investment entities like Militia Capital Partners LP, contrasts the company's robust financial performance. With $1.9 billion in total revenue for 2025, investor trust in Moderna remains strong.
• The introduction of IQVIA.ai, an advanced AI platform developed in partnership with NVIDIA, to enhance operational efficiency and decision-making in the life sciences domain, may have positively influenced market sentiment towards forward-thinking biotech firms like Moderna.
• Criticism directed at the FDA for inconsistent actions, particularly concerning Moderna's vaccine submissions, underscores regulatory uncertainties that could impact the company's future initiatives and market dynamics. Nonetheless, Moderna's resilience and expansion beyond COVID-related products could help mitigate potential risks.

06.02.2026 - MRNA Stock was down 10.0%

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

09.02.2026 - MRNA Stock was down 5.4%

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

11.02.2026 - MRNA Stock was up 5.6%

• Reduction of stake in Moderna by 25.3% by Jefferies Financial Group initially sparked concerns regarding the company's future outlook. However, the strong bullish movement today indicates ongoing investor optimism towards Moderna's growth potential.
• Uptick in Moderna's stock following US vaccine advisors' decision not to question mRNA COVID shots could have boosted investor confidence in the company. This move reaffirms faith in mRNA technology, crucial for Moderna's vaccine innovation.
• Moderna's stock surged 6.13% to hit a day high, outperforming the S&P 500. This indicates a positive market response to the company's recent performance and its potential for future growth, despite past long-term declines.
• Favorable sentiment in the therapeutics sector, marked by companies surpassing revenue expectations, may have also contributed to the bullish movement in Moderna's stock. Investors are demonstrating increased interest in the healthcare industry overall.

12.02.2026 - MRNA Stock was down 5.1%

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.